Table 3.
Frequently used HIPEC regimens in the international peritoneal cancer centers
| HIPEC regimens | Dosage (mg/m2) | Carrier solution | Duration (min) | HIPEC method | Remarks | Consensus for clinical trial (%) |
|---|---|---|---|---|---|---|
| Oxaliplatin-based regimens | ||||||
| 1. Elias high dose oxaliplatin regimen | 460 | 2 L/m2, 5% dextrose solution | 30 | Open | Add 5-FU 400 mg/m2 and leucovorin 20 mg/m2 to separate bags of 250 mL normal saline. Begin rapid intravenous infusion of both drugs 1 h before intraperitoneal chemotherapy | 8.9 |
| 2. Glehen medium dose oxaliplatin regimen | 360 | 2 L/m2, 5% dextrose solution | 30 | Closed | Add 5-FU 400 mg/m2 and leucovorin 20 mg/m2 to separate bags of 250 mL normal saline. Begin rapid intravenous infusion of both drugs 1 h before intraperitoneal chemotherapy | 28.6 |
| 3. Wake Forest University oxaliplatin regimen | 200 | 3 L, 5% dextrose solution | 120 | Closed | NA | 1.8 |
| Mitomycin C-based regimen | ||||||
| 4. Sugarbaker regimen | Mitomycin C, doxorubicin: both 15 mg/m2 | 2 L, 1.5% dextrose peritoneal dialysis solution | 90 | Semi-open | Add 5-FU (400 mg/m2) and leucovorin (20 mg/m2) to separate bags of 250 mL normal saline. Begin rapid intravenous infusion of both drugs simultaneously with intraperitoneal chemotherapy | 1.8 |
| 5. Dutch high dose mitomycin C regimen: “Triple Dosing Regimen” | 35 | 3 L, 1.5% dextrose peritoneal dialysis solution | 90 | Semi-open | Add mitomycin C to the 1.5% peritoneal dialysis solution at a dose of 17.5 mg/m2 followed by 8.8 mg/m2 at 30 min and 8.8 mg/m2 at 60 min | 42.9 |
| 6. American Society of Peritoneal Surface Malignancy low dose mitomycin C regimen: “Concentration-Based Regimen” | 40 mg/3L | 3 L, 1.5% dextrose peritoneal dialysis solution | 90 | Closed | Add mitomycin C to the 1.5% peritoneal dialysis solution at a dose of 30 mg/3 L followed by 10 mg at 60 min | 14.3 |
| 7. PMI Basingstoke IP chemotherapy regimen: “Body Surface Area-based” | 10 | 1 L sodium chloride 0.9% | 60 | Open |
Consider dose reduction by 33% in case of following risk factors: a Obese (BMI > 40) b Severe abdominal distension c Prior heavy chemotherapy (last 3 months) |
10.7 |
| Others | NA | NA | NA | NA | NA | 3.6 |
HIPEC hyperthermic intraperitoneal chemotherapy, NA not applicable